Galectin Therapeutics
(NASDAQ) GALT
Galectin Therapeutics Financials at a Glance
Market Cap
$165.71M
Revenue (TTM)
$0.00
Net Income (TTM)
$30.84M
EPS (TTM)
$-0.59
P/E Ratio
-4.35
Dividend
$0.00
Beta (Volatility)
0.67 (Low)
Dividend
$0.00
Beta (Volatility)
0.67 (Low)
Price
$2.79
Volume
6,628
Open
$2.65
Price
$2.79
Volume
6,628
Open
$2.65
Previous Close
$2.79
Daily Range
$2.65 - $2.79
52-Week Range
$1.12 - $7.13
Dividend
$0.00
Beta (Volatility)
0.67 (Low)
Price
$2.79
Volume
6,628
Open
$2.65
Previous Close
$2.79
Daily Range
$2.65 - $2.79
52-Week Range
$1.12 - $7.13
GALT News
GALT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Galectin Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
15
CEO
Joel Lewis, CPA
Website
www.galectintherapeutics.comHeadquarters
Norcross, GA 30071, US
GALT Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
0%
Return on Capital
0%
Return on Assets
-2%
Earnings Yield
-22.99%
Dividend Yield
0.00%
Payout Ratio
-0.20%
Stock Overview
Market Cap
$165.71M
Shares Outstanding
64.48M
Volume
6.63K
Short Interest
0.00%
Avg. Volume
341.19K
Financials (TTM)
Gross Profit
$0.00
Operating Income
$0.00
EBITDA
$0.00
Operating Cash Flow
$23.88M
Capital Expenditure
$0.00
Free Cash Flow
$23.88M
Cash & ST Invst.
$17.72M
Total Debt
$133.74M
Galectin Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$12.00K
+220.0%
Gross Margin
0.00%
N/A
Market Cap
$165.71M
N/A
Market Cap/Employee
$11.05M
N/A
Employees
15
N/A
Net Income
$5.50M
+54.0%
EBITDA
$19.93M
+294.8%
Quarterly Fundamentals
Net Cash
$116.02M
-27.3%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$133.74M
+57.1%
Short Term Debt
$0.00
-100.0%
Return on Assets
-1.58%
N/A
Return on Invested Capital
0.00%
N/A
Free Cash Flow
$6.04M
+52.8%
Operating Cash Flow
$6.04M
+52.8%